Table 2. Engraftment outcomes .... | American Society of Hematology

Table 2.

Engraftment outcomes

	Filgrastim	Control
Day neutrophils > 0.5 × 10⁹/L	12 (8-18)^*	15 (8-23)^†
Day neutrophils > 1.0 × 10⁹/L	12 (8-25)	16 (9-31+)^‡
Day platelets > 20 × 10⁹/L	15 (9-54+)	11 (6-31+)
Day platelets > 50 × 10⁹/L	20 (12-97+)	16 (10-100+)
Platelet transfusions	8 (2-40)	4 (1-54)
RBC units	6 (1-25)	5 (0-65)
Platelet transfusions/d	0.1 (0.02-1.18)	0.04 (0.01-1.06)
RBC units/d	0.07 (0.01-0.55)	0.05 (0-0.08)
Patients receiving methotrexate
Day neutrophils > 0.5 × 10⁹/L	12 (9-18)	16 (10-23)^2-153

	Filgrastim	Control
Day neutrophils > 0.5 × 10⁹/L	12 (8-18)^*	15 (8-23)^†
Day neutrophils > 1.0 × 10⁹/L	12 (8-25)	16 (9-31+)^‡
Day platelets > 20 × 10⁹/L	15 (9-54+)	11 (6-31+)
Day platelets > 50 × 10⁹/L	20 (12-97+)	16 (10-100+)
Platelet transfusions	8 (2-40)	4 (1-54)
RBC units	6 (1-25)	5 (0-65)
Platelet transfusions/d	0.1 (0.02-1.18)	0.04 (0.01-1.06)
RBC units/d	0.07 (0.01-0.55)	0.05 (0-0.08)
Patients receiving methotrexate
Day neutrophils > 0.5 × 10⁹/L	12 (9-18)	16 (10-23)^2-153

RBC indicates red blood cell.

Median (range).

P = .002 for comparison between filgrastim and control groups.

P = .01 for comparison between filgrastim and control groups.

P = .005 for comparison between filgrastim and control groups.